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ABSTRACT
The oncogenic role of ectopic expression of Na+/H+ exchanger regulatory factor 
1 (NHERF1) was recently suggested. Here, we show that NHERF1 was upregulated in 
high grades compared with low grades. Increased NHERF1 expression was correlated 
with poor prognosis and poor survival. NHERF1 expression was higher in the nucleus 
of cancer cells than in contiguous non- mammary epithelial cells. A novel mutation, 
namely NHERF1 Y24S, was identified in human breast cancer tissues and shown to 
correspond to a conserved residue in the PDZ-I domain of NHERF1.Truncation and 
mutation of the PDZ-I domain of NHERF1 increased the nuclear distribution of the 
NHERF1 protein, and this redistribution was associated with the malignant phenotype 
of breast cancer cells, including growth, migration, and adhesion. The present results 
suggest a role for NHERF1 in the progression of breast cancer mediated by the nuclear 
distribution of the NHERF1 protein, as determined by the truncation or key site 
mutation of the PDZ-I domain.
INTRODUCTION
Na+/H+ exchanger regulatory factor 1 (NHERF1, 
also known as EBP50) was first identified as an essential 
cofactor for cyclic AMP inhibition of Na+/H+ exchange in 
the rabbit renal brush border membrane [1]. It is a scaffold 
protein that is highly expressed in the apical membrane 
of polarized epithelial cells [2]. NHERF1 consists of two 
tandem PDZ domains followed by an ezrin-radixin-moesin 
(ERM)-binding region [3]. NHERF1 can bind to ion 
transporters, G protein-coupled receptors, and cytoskeleton-
associated ERM proteins via these domains, and has been 
implicated in the regulation of diverse biological processes 
associated with ion transport and second messaging 
cascades, as well as in the maintenance of cell polarity [4].
Recent evidence indicates that NHERF1 binds 
many cancer-related proteins, such as phosphate and 
tensin homolog (PTEN) [5, 6], neurofibromatosis 2 
[7], spleen tyrosine kinase [7], platelet-derived growth 
factor receptor (PDGFR) [8], epidermal growth factor 
receptor (EGFR), and β-catenin, suggesting its possible 
involvement in carcinogenesis [7, 9, 10]. NHERF1 mRNA 
levels vary among different human tissues, and NHERF1 
is upregulated in several human s, including hepatocellular 
carcinoma (HCC) [11], breast cancer [12], and colorectal 
cancer [13]. Western blot and immunohistochemical 
analyses of a series of and contiguous non-involved breast 
tissues from the same patients showed that NHERF1 
is highly overexpressed in tissues and associated with 
aggressive clinical characteristics and poor prognosis [14].
The heterogeneous and differential expression of 
NHERF1 is involved in the progression of several types [15, 
16]. NHERF1 expression has been identified in tissues with 
polarized epithelia, with a main intracellular distribution at the 
apical luminal membranes of epithelial cells [17]. Alterations 
in the apical membrane localization of NHERF1 contribute 
to colorectal cancer through the disruption of epithelial 
morphology [18]. Ectopic cytoplasmic NHERF1 expression 
exacerbates the transformed phenotype by increasing cell 
proliferation [18]. Nuclear NHERF1 expression, which is 
Oncotarget2www.impactjournals.com/oncotarget
present in the early stages of carcinogenesis in colorectal 
cancer and is correlated with poor prognosis, may contribute 
to the onset of the malignant phenotype [19, 20]. In a HCC 
model, NHERF1 was found to contribute to transcriptional 
regulation by interacting with and stabilizing the β-catenin 
protein. Stabilized β-catenin translocates and associates with 
different transcriptional factors, acting as a transactivator. 
NHERF1 and β-catenin colocalize in the nucleus of HCC 
cells, and NHERF1 is suggested to function as a positive 
regulator of Wnt signaling and contribute to the malignant 
phenotype [11, 21]. A heterogeneous distribution of 
NHERF1 expression was also observed in the normal breast, 
and in in-situ and invasives, metastatic lymph nodes and 
distant metastases [22]. Cytoplasmic NHERF1 expression 
progressively increases in cells from ductal carcinoma 
in situ (DCIS) to invasive and metastatic tissues, and the 
upregulation of cytoplasmic NHERF1 protein expression 
is accompanied by a progressive and significant decrease 
in membranous NHERF1 expression [22, 23]. These data 
indicate that NHERF1 may be useful as a marker of clinical 
relevance in cancer patients based on its expression and 
cellular distribution. However, the mechanism regulating the 
cellular distribution of the NHERF1 protein remains unclear.
In the current study, we investigated the expression 
pattern and cellular distribution of NHERF1 in human 
breast cancer tissues. The structural factors determining the 
cellular distribution of NHERF1 and the effects of its ectopic 
expression on breast cancer cells were also investigated 
to gain insight into the relationship between NHERF1 
distribution and function, and to improve our understanding 
of the role of NHERF1 in development and progression.
RESULTS
NHERF1 expression was associated with the 
clinical status of breast cancer
The correlation between NHERF1 expression and 
the clinical status of breast cancer patients is summarized 
in Table 1. NHERF1 transcript levels were increased in 
high grades compared with low grades (p = 0.0005, grade 
3 vs. grade 1; p = 0.02, grade 3 vs. grade 2). NHERF1 
upregulation was associated with poor prognosis (p 
= 0.04, NPI-3 vs. NPI-1; p = 0.002, NPI-3 vs. NPI-
2) and decreased overall survival (OS). The mean OS 
was 102.0 [(55.2–148.8, 95% confidence interval (CI)] 
months in patients with high NHERF1 expression levels 
(cut-off by median) and 136.2 (126.6–145.9, 95% CI) 
months in patients with low NHERF1 expression levels 
(Figure 1A). Similar results were obtained for disease-
free survival (DFS), with a mean DFS of 102.0 (55.2–
148.8, 95% CI) months in patients with high NHERF1 
expression levels (cut-off by median) and 130.7 (120.2–
141.3, 95% CI) months in patients with low NHERF1 
expression levels (Figure 1B). No significant differences 
were observed in the OS (p = 0.19) and DFS (p = 0.33) 
curve analyses between patients with high and low 
NHERF1 expression. These results suggest the prognosis 
relevance of NHERF1 expression in breast cancer. 
However, there was no association between NHERF1 
expression in breast cancer tissues and other clinical 
variables including TNM staging and Survival status. 
NHERF1 expression levels did not differ significantly 
between adjacent normal and breast cancer tissues (Table 
1). NHERF1 protein expression was detected at similar 
levels in normal and cancerous epithelial cells, but not in 
surrounding stromal cells (Figure 1C).
Subcellular distribution of NHERF1 in breast 
cancer
To examine the role of NHERF1 in breast cancer, 
NHERF1 expression was detected in the apical membrane, 
cytoplasm, and nucleus of tumor and non-tumor cells 
from patient tissues. Representative images of NHERF1 
immunofluorescence staining are shown in Figure 2. 
NHERF1 immunoreactivity showed mostly an apical 
membranous and cytoplasmic distribution pattern in epithelial 
cells of adjacent non-tumor breast tissues (Figure 2A), 
whereas in cells, NHERF1 was detected in the cytoplasm, 
with large areas of NHERF1 nuclear localization, especially 
in cells that were not polarized (Figure 2A). NHERF1 
protein expression was higher in the nucleus of cancer cells, 
as shown by a higher nucleus/cytoplasm ratio of NHERF1 
staining in breast tumor cells when compared with that in 
non-tumor mammary epithelial cells (p = 0.038) (Figure 2B).
The PDZ-I domain determined the distribution 
of NHERF1 in the membrane and cytoplasm
To identify the structural determinant mediating the 
intracellular distribution of NHERF1, a set of NHERF1 
truncated fragments were generated from the wild-type 
protein (Figure 3A). The imaging results showed that 
the wild-type NHERF1 and PDZ-I domain of NHERF1 
were primarily located in the membrane and cytoplasm. 
Truncation of the PDZ-I domain resulted in a shift in 
the localization of a significant portion of the NHERF1 
protein from the cytoplasm to the nucleus (Figure 3B). 
These data suggested that the PDZ-I domain determines 
the distribution of NHERF1 in the membrane and 
cytoplasm, which could contribute to the regulation of 
NHERF1 function in cells.
The breast cancer-derived NHERF1 Y24S 
mutation increased the nuclear expression 
of NHERF1
The presence of mutation(s), particularly in the 
PDZ-I domain was investigated in 20 frozen breast cancer 
tissues. The coding region and the intron-exon junctions 
of the NHERF1 gene were analyzed by polymerase 
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chain reaction-single strand conformation polymorphism 
(PCR-SSCP) (Supplementary Figure S1A) and confirmed 
by DNA sequencing (Supplementary Figure S1B). A 
previously unknown sequence variant (TAC to TCC) 
was identified in the first exon of NHERF1 in a patient 
with medullary breast carcinoma, which would result in a 
switch of codon 24 (Tyr-Ser). The mutation corresponded 
to a conserved basic residue in the PDZ-I domain 
(Supplementary Figure S1C) [24]. Transient transfection 
of HEK-293 cells with GFP-NHERF1-Y24S resulted 
in an obvious shift in the localization of the NHERF1 
protein from the cytoplasm to the nucleus, compared to 
that in cells transfected with GFP-NHERF1-wt (Figure 
4A). Western blot analysis confirmed that NHERF1-Y24S 
increased the levels of nuclear NHERF1 (Figure 4B).
Breast cancer-derived NHERF1 Y24S mutation 
impaired the tumor-suppressor function of 
NHERF1
To further evaluate the biological role of the 
novel NHERF1 mutation Y24S, wild-type and Y24S 
mutant NHERF1 were stably transfected into MCF-
7ΔNHERF1 (breast cancer cells in which NHERF1 was 
knocked down) cells and its expression was assessed by 
western blotting. The expression level of NHERF1 was 
considerably higher in stably transfected cells than in 
parental or vector control cells, and the Y24S mutation 
was expressed at similar levels than NHERF1-wt (Figure 
5A). Evaluation of malignant phenotypes, including 
cell proliferation, adhesion, and migration, showed an 
approximately 50% lower cell proliferation rate in cells 
overexpressing NHERF1-wt than in parental or vector 
control cells on day 6. Cell adhesion was reduced by 
up to 60% at 40 min, and cell migration was reduced 
by up to 35% at 24 h in NHERF1-wt overexpressing 
compared to parental or vector control cells. However, 
the NHERF1-Y24S mutation lost the tumor-suppressor 
effects observed in NHERF1-wt. (Figure 5B–5D). These 
results indicated that NHERF1-wt acted as a tumor 
suppressor in MCF-7ΔNHERF1 cells, and the breast cancer-
derived NHERF1 mutation Y24S abolished its tumor-
suppressor effects.
Table 1: Quantitative PCR analysis of NHERF1 expression in human breast tissues
Clinical data Grouping No. Mean ± SEM p-value
Tissue sample Normal 31 425±422
Tumor 115 432±313 0.69
Tumor grade 1 20 11.2±9.07
2 39 7.18±4.45 0.02 *(2 vs. 1)
3 54 906±663 0.0005* (3 vs. 1) 0.02* 
(3 vs. 2)
Nottingham Prognostic 
Index (NPI)
1 (<3.4) 58 64.9±50
2 (3.4–5.4) 38 7.79±6.55
3 (>5.4) 15 3024±2346 0.04* (3 vs. 1) 0.002* 
(3 vs. 2)
TNM staging 1 61 656±583
2 37 221±152 0.03*
3 7 1.86±1.22 0.50
4 4 1.33±1.33 0.57
Survival status Disease free 81 458±437
Recurrence 7 12.6±8.05 0.30
Metastasis 5 979±979 0.56
Death 14 305±286 0.15
ER alpha status (-) 69 516±4288
(+) 35 8.62±51 0.63
ER beta status (-) 83 431±3922
(+) 24 167±818 0.10
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The NHERF1 Y24S mutation abolished the 
inhibitory effect of NHERF1 on FBS-induced 
AKT and ERK activation
Next, we detected the phosphorylation status of 
AKT and ERK in MCF-7ΔNHERF1 cells transfected with 
various NHERF1 constructs. Stimulation of MCF-7ΔNHERF1 
parental or vector control cells with FBS for 15 min 
resulted in the marked phosphorylation of AKT (Figure 6A) 
and ERK (Figure 6B). NHERF1-wt overexpression 
significantly inhibited AKT and ERK activation, and 
this effect was partially abolished in cells expressing the 
NHERF1-Y24S mutation (Figure 6). No differences in 
AKT and ERK basal activation levels were detected among 
cells transfected with various NHERF1 constructs (data not 
shown). Taken together, these data suggested that the cancer-
derived NHERF1 mutation Y24S abolished the inhibitory 
effect of NHERF1 on FBS-induced AKT and ERK activation.
Figure 1: Expression of NHERF1 in normal and cancerous human breast tissues. High expression of NHERF1 was associated 
with shorter overall A. and disease-free B. survival of patients with breast cancer. The NHERF1 protein was readily detected in both normal 
and cancerous epithelial cells at a similar level, but not in surrounding stromal cells by IHC C. *p<0.05, **p<0.01.
Oncotarget5www.impactjournals.com/oncotarget
DISCUSSION
In the present study, we found that NHERF1 was 
upregulated in high grade breast cancer patients and 
associated with poor prognosis (Table 1). Patients with 
high NHERF1 expression had a shorter survival time than 
those with low NHERF1 expression (Figure 1). These 
results, which were consistent with those of previous 
studies assessing NHERF1 expression in breast cancer 
[14] confirmed the oncogenic role of NHERF1 in breast 
cancer. However, there was no significant association 
between NHERF1 expression in breast cancer tissues 
and other clinic variables, which could be attributed to 
the large variation in the data. These results suggest that 
the effect of NHERF1 on the progression of breast cancer 
involves other factors in addition to its expression level. In 
Figure 2: Subcellular distribution of NHERF1 in normal and cancerous human breast tissues. Representative images of 
NHERF1 immunofluorescence staining are shown. In contiguous non-tumor breast tissues, NHERF1 showed mostly an apical membranous 
immunoreactivity in epithelial cells A. In the primary tumor and metastatic cells, NHERF1 mostly localized to the cytoplasm, with large 
areas of NHERF1 nuclear localization, especially where cells were not polarized (A). NHERF1 was upregulated in the nuclei of cancer 
cells, as shown by a higher nuclear/membranous ratio of NHERF1 staining in breast cancer cells than in normal mammary epithelial cells 
B. Scale bar, 50 μm; *p<0.05.
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humans, NHERF1 is expressed in many epithelial tissues 
and localizes mainly to the apical luminal membranes of 
epithelial cells [23]. NHERF1 alterations are correlated 
with the progression and invasiveness of human 
tumors, and its heterogeneous distribution is a common 
oncogenic event in carcinomas [10]. Although studies 
have investigated the correlation between cytoplasmic 
overexpression of NHERF1 and oncogenic progression, 
Figure 3: The PDZ-I domain mediated the distribution of NHERF1 in the membrane and cytoplasm. NHERF1 and its 
truncated fragments A. are shown in green, the nucleus is shown in blue, and overlaid images are shown B. Scale bar, 50 μm. Wild-type 
NHERF1 and the PDZ-I domain of NHERF1 localize to the membrane and cytoplasm (B). Truncation of the PDZ-I domain resulted in a 
shift from cytoplasmic to nuclear localization of the NHERF1 protein (B).
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little is known about the involvement of nuclear NHERF1 
in breast cancer. In the present study, we examined the 
effects of ectopic nuclear expression of NHERF1 in 
human breast cancer tissues. Nuclear NHERF1 was 
upregulated in tumor cells, as shown by a higher nuclear/
cytopasmic ratio of NHERF1 immunofluorescence 
staining in breast tumor cells than in adjacent non-tumor 
mammary epithelial cells (p = 0.038) (Figure 2). These 
Figure 4: The cancer-derived NHERF1 Y24S mutation increased the nuclear expression of NHERF1. GFP-NHERF1 
wild-type and the Y24S mutant were expressed in HEK-293 cells. The NHERF1-Y24S mutation resulted in increased nuclear expression 
A. Scale bar, 50 μm. Western blot analysis confirmed that NHERF1-Y24S promoted the nuclear localization of NHERF1 B. The results 
represent the mean values ± SD of three independent experiments (B).*p<0.05.
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results indicated that NHERF1 expression and cellular 
distribution may be useful as markers of clinical relevance 
in cancer patients. However, the mechanism regulating 
NHERF1 cellular distribution remains unclear, and little 
is known about the role of NHERF1 in the nucleus.
NHERF1 is a 358-residue protein comprised 
of two tandem PDZ domains and a C-terminal ERM 
bind region (Figure 3A). Experiments with truncated 
or mutated forms of NHERF1 in epithelial OKP cells 
and in vivo experiments in ezrin(-/-) mice support that 
NHERF1 is stabilized at the epithelial apical membrane 
through its interaction with ERM proteins [25]. Recent 
reports indicate an alternative role for PDZ-domain 
interactions in the recruitment of NHERF1 to the 
membrane. NHERF1 PDZ-I domain is involved in 
membrane recruitment through a phosphorylation switch 
of Ser77 [26]. In the present study, the PDZ-I domain 
was shown to play an important role in the membrane 
and cytoplasmic localization of NHERF1, as shown by 
the nuclear distribution of PDZ-I truncated NHERF1 
Figure 5: The breast cancer-derived NHERF1 Y24S mutation abolished the antitumor effects of NHERF1 in MCF-
7ΔNHERF1 cells. Wild-type and Y24S mutant NHERF1 were stably transfected into MCF-7ΔNHERF1 cells and detected with an anti-NHERF 
antibody A. The Y24S mutation impaired the tumor-suppressor functions of NHERF1, including cell proliferation B. adhesion C. and 
migration D. The results represent the mean values ± SD of three independent experiments (B, C, D). *p<0.05, **p<0.01.
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proteins (NHERF1-PDZII and NHERF1-PDZIΔ) (Figure 
3B). PDZ domains, which are common protein modules 
involved in protein–protein interactions, bind directly to 
the carboxyl (C)-terminal PDZ motifs of their ligands 
[27]. Certain NHERF1-associated proteins bind to the first 
PDZ (PDZ-I) domain, including membrane receptors, such 
as EGFR, PDGFR, β2AR, and CFTR, and cytoplasmic 
proteins such as PTEN and PLCβ [28–30]. The interaction 
of NHERF1 with these proteins could regulate the 
distribution of NHERF1 in the membrane and cytoplasm. 
In addition, the subcellular distribution of NHERF1 could 
affect the interaction between NHERF1 and downstream 
signaling proteins, which could impact the oncogenic role 
of NHERF1 in breast cancer.
The Tyr24 residue plays a key role in the formation 
of the three-dimensional pocket of the PDZ-I domain 
[31–34]. It directly interacts with the Leu 0 of the 
carboxylate group in the interaction with the C-terminal 
end of the binding proteins [32]. In the present study, a 
novel NHERF1 sequence variant (TAC to TCC) resulting 
in a switch of codon 24 (Tyr-Ser) was identified in human 
breast cancer tissues (Suppl Figure 1). Mutation of codon 
24 of NHERF1 could change the three-dimensional 
structure of PDZ-I and impair protein interactions. 
Confocal microscopy showed that transient transfection 
of HEK-293 cells with GFP-NHERF1-Y24S resulted in 
a significant switch in the localization of the NHERF1 
protein from the cytoplasm to the nucleus, compared 
with that in cells transfected with GFP-NHERF1-wt 
(Figure 4). Y24S mutation-induced alterations in the 
interaction between NHERF1 and its ligand proteins in the 
membrane and cytoplasm could decrease the recruitment 
of NHERF1 to the membrane and cytoplasm, resulting in 
its relocalization to the nucleus.
Clinical studies show an association between 
NHERF1 overexpression and the malignant progression of 
cancer [12]; however, contradictory results were reported 
in many in vitro studies indicating a tumor suppressor 
role of NHERF1. NHERF1 overexpression plays a tumor 
suppressor role in breast cancer cell lines, as shown by the 
Figure 6: The Y24S NHERF1 mutation resulted in the loss-of-function of the NHERF1-mediated inhibition of FBS-
induced AKT and ERK activation. MCF-7ΔNHERF1 cells stably transfected with various NHERF1 constructs were serum starved 
overnight, and then stimulated with or without FBS for 15 min. Immunoblotting was performed using anti-pS473AKT A. anti-AKT (A), 
anti-p-ERK B. and anti-ERK (B) antibodies. The signals were quantified by densitometry. Data are expressed as fold change with respect to 
stimulated parental cells. The results represent the mean values ± SD of three independent experiments (A, B). *p<0.05, **p<0.01.
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inhibitory effect of NHERF1 on canonical Wnt signaling 
and Wnt-dependent cell proliferation in MCF-7 and MDA 
MB-231 cells [35]; NHERF1 knockdown accelerates cell 
cycle progression in parallel with increased expression 
of cyclin E and elevated Rb phosphorylation levels [36]. 
Our previous studies also showed that overexpression of 
NHERF1 reduces cell proliferation, motility, and invasion of 
low-NHERF1-expressing SKMES-1 cells, and knockdown 
of NHERF1 enhances the migratory and invasive ability 
of MCF-7 cells [37]. These contradictory results may be 
due to differences in the expression patterns of NHERF1 
in in vivo and in vitro models; for example, the subcellular 
expression pattern may be different in nature and in artificial 
cells, resulting in the activation of different signaling 
pathways and the expression of different cell phenotypes. 
In the present study, in vitro functional experiments showed 
that overexpression of NHERF1 reduced cell proliferation, 
motility, and adhesion in low-NHERF1-expressing MCF-
7ΔNHERF1 cells (Figure 5).
The identification of a novel mutation in this study, 
namely the NHERF1 Y24S mutation, supports the role of 
the NHERF1 protein and the importance of its cellular 
distribution. Truncation (Figure 3) and mutation (Figure 4) 
of the PDZ-I domain promoted the nuclear localization of 
the NHERF1 protein, suggesting that NHERF1 functions 
through the PDZ-II domain in the nucleus. Although only 
a few proteins specifically interact with the second PDZ 
(PDZ-II) domain of NHERF1, many nuclear transcription 
factors are involved, such as β-catenin [11,21] and Yap 65 
[38]. The interaction of NHERF1 with stabilized β-catenin 
functions in transcriptional regulation, suggesting its role 
as a transactivator [21]. The function of NHERF1 in the 
nucleus remains unclear; however, the nuclear localization 
of NHERF1 could promote the interaction between 
NHERF1 and nuclear transcription factors to regulate the 
expression of related signaling proteins, resulting in the 
transformation of cell phenotypes.
Overall, it was showed that NHERF1 upregulation 
was associated with poor prognosis and decreased 
survival time of patients with breast cancer. Nuclear 
NHERF1 protein expression was higher in cancer cells 
than in adjacent non-tumor mammary epithelial cells. 
The truncation and mutation of the PDZ-I domain 
increased the nuclear distribution of NHERF1. NHERF1-
wt overexpression reversed the malignant phenotypes 
of MCF-7ΔNHERF1 cells, including cell proliferation, 
migration, and adhesion. The breast cancer-derived 
NHERF1 mutation Y24S inactivated the inhibitory effect 
of NHERF1 on FBS-induced AKT and ERK activation, 
and resulted in the partial loss of its tumor-suppressor 
effects. These results support the role of NHERF1 in 
tumor development and progression, which could be 
promoted by the nuclear expression of NHERF1. The 
nuclear expression of NHERF1 could be determined by 
the truncation or key site mutation of the PDZ-I domain.
MATERIALS AND METHODS
Cell lines and culture
A human breast cancer cell line with low NHERF1 
expression (MCF-7ΔNHERF1) was generated previously [37] 
by stably expressing a ribozyme targeted to NHERF1. 
HEK-293 cells were obtained from American Type 
Culture Collection (ATCC, Manassas, VA, USA). All 
cells were maintained in Dulbecco’s Modified Eagle’s 
Medium (DMEM) supplemented with 10% fetal calf 
serum, penicillin, and streptomycin (Gibco BRC, Paisley, 
Scotland) in an incubator at 37°C, 5% CO
2
, and 95% 
humidity.
Human breast specimens
A total of 146 breast samples were obtained from 
breast cancer patients (31 were adjacent normal breast 
tissues (> 2 cm to the tumor) and 115 were breast cancer 
tissues). These tissues were collected immediately after 
mastectomy, and snap-frozen in liquid nitrogen, with the 
approval of the Local Ethical Committee. Background 
normal mammary tissues were removed from the same 
patients. The pathologist verified normal background 
and cancer specimens, and background samples were 
confirmed to be free from tumor deposits. The median 
follow-up for the cohort was 120 months (June 2004). The 
relevant information is provided in Table 1. Survival time 
was calculated from the date of surgery, and recurrence or 
metastasis was counted on the date of diagnosis thereof.
RNA preparation and real-time quantitative 
polymerase chain reaction (QPCR)
Total cellular RNA was isolated from the 
homogenized breast samples using the ABgene Total RNA 
Isolation Reagent and following the protocol provided 
(Advanced Biotechnologies Ltd., Epsom, Surrey, UK). 
cDNA was generated from 1 ug of each RNA sample 
and reverse transcribed using a transcription kit (Sigma, 
St. Louis, MO, USA). Quantitative analysis of NHERF1 
mRNA expression in breast tissues was determined by 
QPCR using Amplifor™-based technologies, in which 
a 6-carboxy-fluorescine-tagged Uniprimer™ (Biosearch 
Technologies, Inc., Petaluma, CA, USA) was used as 
a probe together with a pair of target-specific primers 
and reverse primer with an additional Z-sequence 
(actgaacctgaccgtaca) (NHERF1 QPCR primers – sense: 
AGGGAAACTGACGAGTTCTT; antisense: ACTG
AACCTGACCGTACATTCACGACTGTTCTCCTT
CT). Real-time QPCR conditions were 95°C for 15 min, 
followed by 60 cycles at 95°C for 20 s, 55°C for 30 s 
and 72°C for 20 s. The quality of cDNA samples was 
verified using β-actin as a housekeeping gene (β-actin 
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QPCR primers – sense: CATTAAGGAGAAGCTGTGCT; 
antisense: ACTGAACCTGACCGTACAGCTCGTAGCT
CTTCTCCAG). The epithelial content within the tumors 
was taken into account by normalizing NHERF1 levels 
against cytokeratin 19 (CK19 primer details- sense: 
CAGGTCCGAGGTTACTGAC; antisense: ACTGAAC
CTGACCGTACACACTTTCTGCCAGTGTGTCTTC).
Immunohistochemical and immunofluorescence 
staining of breast specimens
Frozen sections of breast tumors (n=25) (8 Grade-1, 
8 Grade-2, and 9 Grade-3) and background tissues (n=25) 
were selected from the tissue bank and cut at a thickness 
of 6 μm using a cryostat. The sections were fixed in a 
mixture of 50% acetone and 50% methanol and then 
placed in ‘Optimax’ wash buffer for 5-10 min to rehydrate. 
Sections were incubated for 20 min in a horse serum 
blocking solution and probed with monoclonal mouse 
anti-human NHERF1 primary antibody (1:200) (Santa-
Cruz Biotechnologies, Santa Cruz, CA, USA). This study 
employed controls that omitted the primary and secondary 
antibodies. For immunohistochemical staining, following 
extensive washings, sections were incubated for 30 min 
in the secondary biotinylated antibody (1:100) (Multilink 
Swine anti-goat/mouse/rabbit immunoglobulin, Dako Inc., 
Copenhagen, DK). Following washings, the Avidin Biotin 
Complex (Vector Laboratories, Peterborough, UK) was 
then applied to the sections, followed by extensive washing 
steps. Diamino benzidine chromogen (Vector Labs) was 
then added to the sections, and incubated in the dark for 5 
min and counterstained by hematoxylin. Sections were then 
dehydrated in ascending grades of methanol before clearing 
in xylene and mounting under a cover slip.
For immunofluorescence staining, the TRITC-
conjugated secondary antibody (Invitrogen, Paisley, 
Scotland, UK) was subsequently added to the slides, 
and the slides were incubated on a shaker platform in 
the dark for 1 h. After washing three times to remove the 
unbound secondary antibody, cell nuclei were stained 
with Hoechst 33258 (Sigma). The slides were finally 
mounted with FluorSave™ (Calbiochem-Novabiochem 
Ltd., Nottingham, UK) and visualized with a confocal 
microscope (Leica Microsystems LAS AF-TCS SP5. 
Wetzlar, Germany). Immunostaining reaction intensity 
and area [integral optical density (IOD)] for NHERF1 
were separately assessed by 2 independent authors who 
were blinded to the tissue grouping using computer-
assisted morphological analysis. Image Pro Plus 6.0 
(Media Cybernetics, Inc., Rockville, MD, USA) was 
used to calculate the intensity and extent of staining for 
NHERF1, and the ratio of the nucleus staining area to the 
cytoplasma area of the image in the different tissues. A 
total of 10 microscopic fields were randomly selected, and 
their images were cropped. Results were expressed as the 
mean ± standard deviation (SD).
Mutational analyses
The genomic DNA from 20 frozen breast cancer 
tissues was extracted using the DNeasy kit (Qiagen, Hilden, 
Germany). All six exons of the NHERF1 gene were amplified 
by PCR using primers corresponding to the neighboring 
intronic sequences, and further analyzed by SSCP as 
previously described [39]. Primers were: exon 1 (forward, 
5′-tgggacacctgcttgcttg-3′; reverse, 5′-atcctcctcccactccatg-3′); 
exon 2 (forward, 5′-aattgctgtgtagggatctag-3′; reverse, 
5′-ggaagagagcgagaagcatc-3′); exon 3 (forward, 5′-actgcaaa 
ctggctgagaac-3′; reverse, 5′-tggctcacatccctgacttg-3′); exon 4 
(forward, 5′-attcatggtgggtggtagtc-3′; reverse, 5′-caccttctg 
atctgtctcatg-3′); exon 5 (forward, 5′-aggctcaggaggtgggaac-3′; 
reverse, 5′-ggcttcctgtaacccagttg-3′); and exon 6 (forward, 
5′-agccgcattctgttcttgtg-3′; reverse, 5′-gaaaaaggtggggtgg 
aatg-3′). The candidates of mutant gene were then identified 
by DNA sequencing.
Preparation of plasmids and fusion proteins
NHERF1 cDNA was cloned into pEASY™-M2 and 
pcDNA3.1 vector by using pEASY-Blunt M2 Expression 
Kit (TransGen, Beijing, China) and pcDNA3.1/CT-
GFP TOPO TA expression kit (Invitrogen) to obtain the 
NHERF1 and GFP-NHERF1 expression constructs, 
according to the manufacturer’s instructions. The 
constructs of the NO-tagged and GFP-tagged NHERF1-
Y24S mutant were generated from the wild type with 
the use of the Fast MultiSite Mutagenesis System kit 
(TransGen). The PDZ-I domain (amino acids 1–97 of 
the human NHERF1 protein, NHERF1-PDZI), the PDZ-
II domain (amino acids 150–237 of human NHERF1 
protein, NHERF1-PDZII) and the NHERF PDZ-I domain 
truncation fragment (amino acids 150–358 of the human 
NHERF1 protein, NHERF1-PDZIΔ) were amplified by 
PCR and subcloned into pcDNA3.1/CT-GFP as GFP 
fusion proteins.
Cytoplasmic and nuclear extracts
Cells were cultured in 10-cm plates for 48 h. After 
washing with cold PBS once, cells were harvested in 1000 
μl of cold PBS. Cells were centrifuged (2 min, 500 g) at 
4°C, washed twice with cold PBS, and resuspended in 
400 μl of cold lysis buffer (10 mM HEPES, 50 mM NaCl, 
5 mM EDTA, 1 mM Benzamidine, 0.5% Triton X-100). 
The lysates were then solubilized via vortex for 15 s and 
placed on ice for 20 min. The resulting homogenate was 
centrifuged for 1 min (2,000 g) at 4°C and the supernatant 
was kept as the cytoplasmic fraction. The precipitate was 
resuspended in 40 μl nuclear lysis buffer. The lysates were 
placed on ice for 40 min and solubilized via vortex for 15 
s every 10 min. The resulting homogenate was centrifuged 
for 10 min (16,000 g) at 4°C and the supernatant was kept 
as the nuclear fraction. Samples were stored at −80°C.
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Western blotting and antibodies
Western blotting was performed as described 
previously [40]. The anti-NHERF1and anti-pS473AKT 
antibodies were purchased from Cell Signaling 
Technology (Danvers, MA, USA); anti-AKT antibody was 
from Sigma; anti-α-Tubulin, anti-HDAC and anti-GAPDH 
were from Santa Cruz Biotechnology; anti-GFP and anti-
His antibodies were from MBL (Tokyo, Japan).
Cell proliferation assay
Cell viability was evaluated using a nonradioactive 
cell counting kit (CCK-8, Dojindo, Kamimashiki-gun, 
Kumamoto, Japan) according to the manufacturer’s 
instructions. Cells were seeded in a 96-well plate at a 
density of 3000 cells per well, and after every 24 h, the 
CCK-8 reagent was added to each well and the plates 
were incubated for an additional 1 h at 37°C. Cell 
viability was measured as the absorbance at 450 nm with 
an Elx800™ spectrophotometer (BioTek, Winooski, VT, 
USA).
Wound-healing assay
The migratory properties of cells were assessed by 
wound-healing assay. Cells were seeded at a density of 2 
× 105 cells/well into a 24-well plate and allowed to reach 
confluence. The layer of cells was then scraped with a 
fine gauge needle to create a wound of approximately 
1500 μm. Images of the wound were recorded under a 
phase contrast microscope at different times (0, 6, 12, 
and 24 h). Wound closure/cell migration was evaluated 
with motion analysis and line morphometry software 
(Optimus 6).
Cell adhesion assay
A 96-well plate was pre-coated with 5 μg/well of 
Matrigel (BD Biosciences, Oxford, UK). Cells were 
seeded at a density of 2 × 105 cells/well. After incubation 
at 37°C with 5% CO
2
 for 40 min, the cells were fixed, 
stained, and quantified as described previously [41].
Statistical analysis
SPSS version 16.0 (SPSS, Inc., Chicago, IL, 
USA) was used for statistical analyses. The results were 
assessed using non-paired (two-sided) Student’s t-test and 
Mann-Whitney U-test. Overall and disease-free survival 
rates were calculated using the Kaplan-Meier method. 
The log-rank test was utilized to compare the survival 
rates between groups with varying NHERF1 expression 
levels. The association of expression with the clinical 
and pathological features was analyzed using one-way 
ANOVA. A p-value <0.05 was defined as statistically 
significant.
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